Oligonucleotide Therapy for Obstructive and Restrictive Respiratory Diseases

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Molecular Biology

Background:

• Chronic respiratory diseases like asthma, COPD, and IPF involve persistent inflammation and tissue remodeling.
• Corticosteroids are common treatments but face limitations due to steroid resistance.
• There is a critical need for novel, targeted therapies for these conditions.

Purpose of the Study:

• To review current findings on oligonucleotide therapeutic targets for respiratory diseases.
• To evaluate chemical modifications enhancing oligonucleotide stability and potency.
• To assess the potential of inhaled oligonucleotides as a targeted lung therapy.

Main Methods:

• Review of pre-clinical and clinical studies on oligonucleotide therapies (ASO, siRNA, miRNA).
• Analysis of mechanisms of action, including mRNA and protein knockdown.
• Evaluation of chemical modifications for improved oligonucleotide therapeutics.

Main Results:

• Oligonucleotide therapies demonstrate target-specific mechanisms for respiratory diseases.
• Inhaled administration offers direct lung access, minimizing systemic side effects.
• Various chemical modifications are being explored to boost oligonucleotide efficacy.

Conclusions:

• Inhaled oligonucleotides represent a promising therapeutic strategy for asthma, COPD, and IPF.
• Targeted oligonucleotide therapies address limitations of current treatments like corticosteroids.
• Further research into oligonucleotide targets and modifications is crucial for advancing respiratory medicine.